Figure 2. Time-to-treatment Failure (TTF) in the METEORA-II Trial.

The end-of-treatment date for defining TTF was the date the last paclitaxel intravenous dose was administered plus 7 days or the date when at least 1 of the 3 oral medications (vinorelbine plus cyclophosphamide plus capecitabine) was taken for the last time. A maximum 3-week delay of administration of any study medication was allowed. VEX indicates vinorelbine plus cyclophosphamide plus capecitabine.